Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) –

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.

Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe

Amarin's Vazkepa notched a crucial win with a European regulator. The medication earned an extension to its patent exclusivity on that market.

Why Amarin Stock Was Rocketing Higher on Wednesday

Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039 Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

-- Subgroup Analyses from REDUCE-IT ® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting --    DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology's Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA.

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.

Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 -- -- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash Flow of $10 Million --  -- Company Reports Fourth Quarter 2023 Total Operating Expense of $50 Million -- -- Initiated Shareholder Approval Process to Execute a Share Repurchase Program of up to $50 Million by the End of the Second Quarter 2024 -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter and year ended December 31, 2023 and provided an update on the Company's operations.

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February 29th, 2024, at 8:00 a.m. ET. The call will include brief remarks on 2023 highlights followed by Q&A.

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Beam Therapeutics

BioMarin Pharmaceutical

Moderna

Intellia Therapeutics

Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders:

Amarin Chairman & CEO Issue Letter to Shareholders

Sarissa Capital is successfully turning around Amarin, giving it new life and potential for success. Amarin's REDUCE-IT trial proved the cardiovascular benefits of its purified EPA product, Vascepa, leading to its potential for greatness. The implementation of strategic proposals, a new CEO with relevant expertise, and higher than expected Q4 earnings are positive signs for Amarin's future.

Amarin: Sarissa Is Giving Me Hope Again

Here is how Amarin (AMRN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Amarin (AMRN) This Year?

Amarin (AMRN) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million.

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

Amarin announced better-than-expected fourth-quarter results on Wednesday. The biopharmaceuticals company also announced a $50 million share repurchase program and guidance on capital allocation for 2024.

Why Amarin Stock Skyrocketed Today

Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

Amarin Corporation rose by more than a quarter on Wednesday after the drugmaker reported preliminary fourth-quarter revenues well ahead of analysts' expectations. In a business update ahead of its presentation to a J.P.

Amarin stock soars on preliminary 4Q revenue guidance, share buyback plan

-- Reported Unaudited Total Revenues of Between $72 Million - $74 Million in the Fourth Quarter of 2023 -- -- Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive Cash Flow of ~$10 Million --

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amarin's president and chief executive officer, Patrick Holt, is scheduled to present at the conference on January 10, 2024.

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Amarin (AMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Amarin (AMRN) a New Buy Stock

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa believes Amarin's stock is significantly undervalued. We continue to believe in both the tremendous value of Vascepa/Vazkepa to cardiovascular patients worldwide and the market opportunity. We are very upset that the stock has remained low. We expect that over time that value will be reflected in the stock price. We hope that.

Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership

-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo -- -- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease --

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

Amarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year.

Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates

Amarin Corporation plc (NASDAQ:AMRN ) Q3 2023 Earnings Call Transcript November 1, 2023 8:00 AM ET Company Participants Jordan Zwick - SVP, Business Development & IR Patrick Holt - President & CEO Tom Reilly - CFO Conference Call Participants Louise Chen - Cantor Roanna Ruiz - Leerink Paul Choi - Goldman Sachs Operator Welcome to Amarin Corporation's conference call to discuss its third quarter 2023 financial results and business updates. I would now like to turn the conference call over to Jordan Zwick, Senior Vice President, Business Development and Investor Relations at Amarin.

Amarin Corporation plc (AMRN) Q3 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Amarin (AMRN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

News for Amarin Corporation Plc Stock (AMRN)